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Human monoclonal antibodies that neutralize
anthrax toxin by inhibiting heptamer
assembly
Fei Wanga, Paul Ruthera, Ivy Jianga, Ritsuko Sawada-Hiraia, Shu Man Suna, Rebecca Nedelleca,b,
Phillip R. Morrowa and Angray S. Kanga,∗
aAvanir Pharmaceuticals, Antibody Technology, 11388 Sorrento Valley Rd, San Diego, CA 92121, USA
bCurrent affiliation: Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
Abstract. A panel of human anti-anthrax protective antigen IgG1 monoclonal antibodies were evaluated to determine the
mechanism of toxin neutralization. AVP-22G12, AVP-1C6 and AVP-21D9 bound to the protective antigen with picomolar
affinities to distinct non-overlapping linear epitopes. Two of the antibodies neutralized the anthrax toxin by completely inhibiting
the protective antigen oligomer assembly process in vitro.
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1. Introduction
Inhalation of anthrax spores can be fatal if not treated
immediately with antibiotics. The interval between the
onset of symptoms and death can be very short, hours
rather than days in situations where aggressive treat-
ment is not applied. This is in part due to the pathogen
Bacillus anthracis, which utilizes two distinct strate-
gies to evade immune surveillance, thus facilitate dis-
semination throughout the body and a rapid rise in bac-
teremia. Initially, upon exposure to spores, the capsule
composed of poly-D-glutamic acid provides a physical
barrier to circumvent phagocytosis. Secondly, via the
concerted effect of three proteins, protective antigen
(PA), lethal factor (LF), and edema factor (EF) [1–3]
the immune response against the invading bacteria is
compromised. PA is a 83 kD protein that binds to tumor
endothelial marker-8 (TEM-8) [4] or human capillary
morphogenesis protein –2 (CMG-2) [5], collectively
∗Corresponding author: Avanir Pharmaceuticals, Antibody Tech-
nology, 11388 Sorrento Valley Rd, San Diego, California 92121,
USA. Tel.: +1 858 622 5294; Fax: +1 858 658 7458; E-mail:
fwang@avanir.com.
called the anthrax toxin receptors (ATRs). The recep-
tors are found on both macrophages and endothelial
cells. The membrane bound PA83 is cleaved by a furin
or furin like protease to PA63, which spontaneously
assembles into a 7-member oligomer. A hypothetical
model of the receptor bound membrane-inserted PA
pore has recently been described [6]. This PA63 hep-
tamer facilitates the entry of LF/EF, which then exert an
initial immunosuppressive [7] and ultimately toxic ef-
fect [8]. LF is a protease that inhibits mitogen-activated
protein kinase-kinase [9], which reduces the cytokine
production by macrophages and ultimately leads to cell
death. EF is an adenylate cyclase that generates cyclic
AMP in eukaryotic cells [10] and impairs the ability of
neutrophils to engulf bacteria.
The anti-toxin activity of both polyclonal and mon-
oclonal anti-PA antibodies is well documented [11–
13]. Moreover it has been shown that the combination
of toxin neutralization with antibodies and inhibition
of bacterial growth by antibiotics is very effective in
a small animal anthrax challenge model [14]. Anti-
anthrax toxin antibodies, which neutralize the immuno-
suppressive effects of PA/LF/EF, working in concert
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Fig. 1. Sensogram of sequentially bound anti-PA antibodies, demonstrating that irrespective of the order of binding all three human monoclonal
anti-PA83 antibodies (AVP-21D9, 22G12 and 1C6) can bind to a single PA83 molecule. The CM-5 chip was coated with a anti human IgG
capture antibody, first antibody was applied, followed by pooled human IgG blocking antibody, PA83 followed sequentially with the 2nd and 3rd
antibodies. The order in which the antibodies were applied was changed in subsequent runs to cover all permutations.
with conventional antibiotics may provide additional
protection in the event of an anthrax spore exposure.
A panel of 3 high affinity fully human anti-anthrax
PA antibodies that neutralize anthrax toxin in vitro and
in vivo generated from anthrax vaccine adsorbed (AVA)
vaccinated donors have been described [15]. Here the
mechanism of antibody mediated toxin neutralization
is described.
2. Materials and methods
The binding of the monoclonal antibodies to distinct
or overlapping epitopes on PA83 was determined by
surface plasmon resonance. Anti-human IgG capture
antibody (goat anti-human Fc gamma specific, Jackson
Immuno Research, PA) was coupled to a CM-5 chip
through standard amine chemistry using an immobi-
lization guide provide by the Biacore (Biacore Inc, NJ),
whereby a response unit (RU) value of 10,000 units was
approached. The first human monoclonal antibody was
applied, followed by pooled human (non-immune) IgG
blocking antibody,PA83 (PA83, and LF both purchased
from List Biological Labs, CA) followed sequentially
with the 2nd and 3rd monoclonal antibodies. The or-
der in which the antibodies were applied was changed
in subsequent runs to cover all permutations. The test
reagents (PA, MAbs) were applied at 20 µg/ml in HBS-
EP buffer provide by Biacore, the blocking antibody
human IgG1/κ (Sigma Co, MO) was used at 40 µg/ml.
The resulting binding data is presented in a sensogram
Fig. 1.
To map the antibody recognition to distinct portion
of the PA83, western blot analysis was undertaken. In
Fig. 2(a), a schematic of fragments of PA83 generated
by trypsin and chymotrypsin digestion based on the se-
quences and mapping studies previously described [16,
17] is shown. Intact PA83, trypsin, chymotrypsin or
combination of trypsin and chymotrypsin generated PA
fragments were probed with human monoclonal an-
tibodies AVP-1C6, AVP-22G12 and AVP-21D9 in a
western blot (Fig. 2(b)).
To investigate whether the antibody bound to
PA83 blocked subsequent processing, PA83 was pre-
incubated with antibodies, then, treated with trypsin,
and the resulting mixtures were analysed by SDS-
PAGE and Coomassie staining (Fig. 2(c)).
The role of antibodies in inhibiting the binding of
lethal factor to PA 63 oligomer was again investigated
by surface plasmon resonance. PA63 (PA63 oligomer,
List Laboratories, CA) was immobilized on a Bia-
Core CM5 chip, essentially as described above, anti-
body captured and lethal factor applied. The binding
events were monitored and are presented in a senso-
gram (Fig. 3(a)). Also the role of antibodies in block-
ing binding of the anthrax toxin PA83 to its receptor
was investigated in a similar manner. Anti-human Fc
gamma was conjugated to the CM5 chip, human mono-
clonal anti-PA antibody captured, PA83 bound and sol-
uble anthrax toxin receptor applied, again each bind-
ing event was monitored by surface plasmon resonance
(Fig. 3(b)).
Finally, to determine if the antibodies inhibited the
formation of PA63 heptamer equimolar amounts of












































Fig. 2. Identification of protective domains on PA83. (a) A schematic of fragments of PA83 generated by trypsin and chymotrypsin digest
based on the sequences and mapping studies [16,17]. (b) Western blot analysis of intact (I), trypsin (T), chymotrypsin (C) and combination of
trypsin and chymotrypsin (T+C) generated PA fragments probed with AVP-1C6, AVP-22G12 or AVP-21D9. (c) Coomassie stained SDS-PAGE
of antibody bound PA83 treated with trypsin. Lane (1) Molecular weight markers; (2) PA83 no trypsin; (3) no antibody; (4) AVP-22G12; (5)
AVP-21D9; (6) AVP-1C6; (7) AVP-1451 isotype matched human IgG anti-tetanus control.
PA83 (0.25 nmol) and anti-PA antibody (0.25 nmol)
were mixed in 70 µl of PBS. After 30 minutes incuba-
tion at room temperature the mixture was transferred to
4◦C and 10 µl of ice-cold trypsin (50 µg/ml) was added
for 5 minutes. Trypsin was inactivated by the addition
of 5 µl trypsin and chymotrypsin inhibitor (10 mg/ml).
Citric phosphate buffer (115 µl of 0.1 M, pH5.0) was
then added to bring the pH to 5.0 to facilitate PA63
oligomerization. SDS loading buffer was added and
the mixtures placed on boiling water for 10 minutes.
Polypeptides were separated in a 10% Bis-Tris gel un-
der reducing condition. Protein bands were visualized
















Fig. 3. Interaction of human anti-anthrax PA antibodies with (a) PA63 and lethal factor and (b) PA83 and soluble anthrax toxin receptor by surface
plasmon resonance. (a) PA 63 oligomer was immobilized on a BiaCore CM5 chip, antibody captured and lethal factor applied. (b) Anti-human
Fc gamma conjugated to BiaCore CM5 chip, human monoclonal anti-PA83 antibody captured, PA83 bound and soluble anthrax toxin receptor
applied (plasmid encoding full-length ATR a kind gift from Dr. Ken Bradley, UCLA).
by Coomassie blue staining (Fig. 4).
3. Results and discussion
Sequential binding of anti-PA antibodies to PA83
indicated that they bound to distinct non-overlapping
epitopes (Fig. 1). Western blot analysis of intact PA
83 indicated all three antibodies recognized linear epi-
topes on PA83 (Fig. 2(a,b)). AVP-21D9 and AVP-1C6
mapped to the carboxyl domain PA47 generated by chy-
motrypsin digest. The binding of AVP-22G12 mapped
to the chymotrypsin generated fragment PA37 which
contains the natural furin cleavage site [17]. Treating
PA83 with trypsin abolished AVP-22G12 binding in the
western blot (Fig. 2(b)). Initially this suggested that
AVP-22G12 itself might act by inhibiting the cleavage
of PA83 to PA63. To test this hypothesis, PA83 was
pre-incubated with antibody prior to trypsin addition,
the resulting mixture was analysed. Surprisingly, AVP-
22G12 bound to PA83 permits cleavage by trypsin, im-
plying that it binds close to (and possibly spans) the
accessible cleavage site (Fig. 2(c)).














Fig. 4. Effects of Anti-PA antibodies on PA63 oligomer formation.
Coomassie stained SDS-PAGE of antibody bound PA83 treated with
trypsin. Lane assignment: Molecular weight markers; (1) PA83
trypsin treated no antibody; (2) AVP-22G12; (3) AVP-21D9; (4)
AVP-1C6; (5) AVP-1451 isotype matched human IgG anti-tetanus
control.
Equal molar of PA83 (0.25 nmol) and PA-ab (0.25 nmol) were mixed
in 70 µl of PBS. After 30 minutes incubation at room temperature
the mixture was transferred to 4◦C and trypsin (50 µg/ml) 10 µl
of ice-cold added for 5 minutes. Trypsin was inactivated by the
addition of 5 µl trypsin and chymotrypsin inhibitor (10 mg/ml). Citric
phosphate buffer (115 µl of 0.1 M, pH5.0) was then added to bring
the pH to 5.0 to facilitate PA63 oligomerization. SDS loading buffer
was added and the mixtures boiled for 10 minutes. Polypeptides were
separated in a 10% Bis-Tris gel running under reducing condition.
Protein bands were visualized by Coomassie blue staining.
To determine whether the antibodies efficacy was in
part due to inhibiting LF binding to PA63 oligomer,
the interactions between PA63 oligomer, antibody and
LF were investigated. AVP-22G12 did not bind to pre-
formed PA63 oligomer, thus by default did not appear
to compete for EF/LF binding; though AVP-21D9 had
very weak binding (possibly due to the presence of a
small amount of PA63 monomer) and AVP-1C6 bound
to the PA 63 oligomer, neither inhibited LF binding
(Fig. 3(a)). All the antibodies bound PA83, which sub-
sequently bound soluble ATR (sATR) (Fig. 3(b)). How-
ever partial inhibition of sATR binding was observed
on AVP-1C6 captured PA83, hinting at a possible mode
of action.
AVP-21D9 and AVP-22G12 did not inhibit PA83
sATR interaction, nor did they appear to prevent sub-
sequent processing to PA63 or the binding of LF to
PA 63 oligomer, yet paradoxically they were the two
most potent inhibitors of anthrax lethal toxin (PA/LF)
in vitro and in vivo in rats [15]. AVP-22G12 bound to
native PA83, denatured PA83 and PA37, but not to the
preformed heptamer or monomer PA63. These obser-
vations implied that at least for AVP-22G12 the step
of toxin neutralization probably occurred prior to hep-
tamer assembly. In a natural exposure to anthrax, upon
cleavage of PA83 to PA63 and the release of PA20, the
PA63 spontaneously forms a heptamer [8].
An oligomer of PA63 can be formed in vitro by treat-
ing PA83 with trypsin and is stable in the presence
of sodium dodecyl sulphate (SDS) as shown in lane
1 of Fig. 4. Antibody bound PA83 was cleaved by
trypsin to mimic the natural furin like protease, to gen-
erate PA63-PA20. pH was adjust to 5.0 to facilitate
heptamer assembly. The mixtures were examined by
SDS-PAGE. In the absence of anti-PA antibody (lane
1) or in the presence of an isotype matched control
antibody (lane 5), the PA63 oligomer formed readily.
Both AVP-22G12 and AVP-21D9 (lanes 2 and 3) com-
pletely inhibited heptamer formation (Fig. 4). Since
western blot analysis had shown that the two antibod-
ies bind to distinct regions of PA83, clearly the anti-
bodies prevented the oligomer formation via distinct
mechanisms. It was demonstrated that AVP-22G12
binds to a linear epitope on PA83 that possibly spans
PA63 and PA 20 cleavage site, but still permits ac-
cess to protease site and the clipped molecule retains
PA20. It is plausible that the retention of PA20 on the
antibody-antigen complex may hinder the subsequent
heptamer formation. Whereas, AVP-21D9 bound to a
distal linear epitope within the PA47 polypeptide and
prevented PA oligomer formation possibly by masking
potential assembly interfaces. It has previously been
demonstrated that correct pore assembly is absolutely
essential to facilitate LF and EF entry into cells [18],
thus blocking this portal molecule effectively protects
against the effects of both EF and LF anthrax toxin(s).
This is the first report of fully human antibodies gen-
erated in response to AVA vaccination that neutralize
anthrax exotoxin PA by preventing PA63 oligomer as-
sembly. Identification of the epitope for AVP-21D9
may further add to the understanding of the self-
assembly process and the development of site directed
therapeutic interventions (such as AVP-21D9). The 3
antibodies described may also be therapeutically useful
against anthrax infection and may have utility as pro-
phylactic agents for at risk non-vaccinated individuals.
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